Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 92 от 222

Recruiting Phase 3

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.

Начало: 04.06.2025 Край: 15.08.2029 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +18 Janssen Research & Development, LLC NCT06852222

Recruiting

Mobile Health Technology-Enabled AFib Management

Atrial Fibrillation Behavior

The overall objective of this proposal is to evaluate the effect on quality of life of a comprehensive digital atrial fibrillation (AFib) management tool that will empower patients to a) take an active role in learning about AFib management options, starting and adhering to evidence-based therapies and lifestyle changes and b) to guide the patients during AFib episodes which are associated with anxiety and impairment in quality of life. Researchers plan to evaluate the effectiveness of this novel digital toolkit in improving quality of life and decreasing AFib burden in a randomized clinical trial (RCT). A pilot study assessing feasibility and retention of the intervention was previously conducted (NCT05400837)

Начало: 03.06.2025 Край: 01.06.2028 Възраст: от 18 г.

United States Johns Hopkins University NCT06500988

Recruiting

Trial for Reliability of Urodynamics SysTem

Urologic Diseases Urodynamics

The goal of this prospective trial is to assess the safety and reliability of the Glean Urodynamics System (GUS) in adult females with lower urinary tract symptoms. The main question\[s\] it aims to answer are: • What is GUS's ability to safely and reliably conduct wireless, catheter-free monitoring of vesical pressure compared to the vesical pressures collected with conventional urodynamics? Participants will undergo a conventional urodynamics exam, a simultaneous urodynamics exam with GUS, ambulatory urodynamics with GUS, and extended home monitoring with GUS. Researchers will compare GUS data with that from a conventional urodynamics exam.

Начало: 03.06.2025 Край: 01.07.2026 Възраст: от 18 г.

United States Bright Uro NCT05694793

Recruiting

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

Persistent Atrial Fibrillation

The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.

Начало: 03.06.2025 Край: 01.01.2028 Възраст: от 18 г. Treatment

Australia, Taiwan, United States Boston Scientific Corporation NCT06735534

Recruiting Phase 3

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Asthma

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Начало: 03.06.2025 Край: 11.02.2028 Възраст: от 18 г.

Belgium, Canada, China +8 GlaxoSmithKline NCT06979323

Recruiting Phase 1

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

Healthy

The aim of this study is to investigate the safety and tolerability of HB0043 in healthy subjects following single-dose.

Начало: 03.06.2025 Край: 01.04.2026 Възраст: 18–55 г. Other

New Zealand Shanghai Huaota Biopharmaceutical Co., Ltd. NCT06999083

Recruiting Phase 2

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

Crohn's Disease

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Начало: 03.06.2025 Край: 17.10.2029 Възраст: 18–75 г. Treatment

Australia, Belgium, China +9 Sanofi NCT06958536

Recruiting Phase 1

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Acne

This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be a randomized, open-label, 2-way crossover investigation to assess the effect of food on a single dose TVB-3567 administered orally in healthy participants. Parts C and D will be randomized, double-blind, placebo-controlled investigations of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants without and with moderate to severe acne, respectively.

Начало: 03.06.2025 Край: 01.06.2026 Възраст: 18–55 г. Treatment

Australia, United States Sagimet Biosciences Inc. NCT06989840

Recruiting

Imaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors

Childhood Cancer Muscle Weakness

The participants are being asked to take part in this trial, because the participant is a survivor of childhood cancer or agreed to be part of a volunteer group to understand the relation between cancer and cancer treatment and muscle weakness in survivors of Acute Lymphoblastic Leukemia (ALL). ALL is cancer of the blood and bone marrow. Primary Objective • To compare muscle mtOXPHOS activity and satellite cell content among ALL survivors and controls. Secondary Objective * To evaluate the association between muscle mtOXPHOS, muscle satellite cell content and physical performance in ALL survivors. * To evaluate the association of muscle morphology and epigenetics with muscle mtOXPHOS in ALL survivors.

Начало: 02.06.2025 Край: 01.01.2028 Възраст: от 18 г.

United States St. Jude Children's Research Hospital NCT06819475

Recruiting Phase 2

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Mantle Cell Lymphoma +5

This phase II trial studies the side effects of an escalated ramp-up of sonrotoclax following initial debulking with zanubrutinib or rituximab in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) that is newly diagnosed, has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill tumor cells. Zanubrutinib may stop the growth of tumor cells by blocking a protein called Bruton's tyrosine kinase (BTK), which is needed for tumor cell growth. Sonrotoclax works by blocking a protein called B-cell lymphoma-2 (BCL-2). This protein helps certain types of blood tumor cells to survive and grow. When sonrotoclax blocks Bcl-2 it slows down or stops the growth of tumor cells and helps them die. Giving an increased dose of sonrotoclax over a shorter period of time in combination with zanubrutinib or rituximab may be safe and tolerable in treating patients with newly diagnosed, relapsed or refractory CLL, SLL, and MCL.

Начало: 02.06.2025 Край: 01.07.2032 Възраст: от 18 г.

United States Fred Hutchinson Cancer Center NCT06839053

Recruiting

Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study

Deep Vein Thrombosis Venous Thromboembolism Pulmonary Embolism

This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.

Начало: 02.06.2025 Край: 01.12.2030 Възраст: от 18 г.

Spain, United Kingdom, United States Cook Research Incorporated NCT05881798

Recruiting Phase 2

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC) UC - Ulcerative Colitis

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.

Начало: 02.06.2025 Край: 01.11.2026 Възраст: 18–75 г. Treatment

Australia, Canada, Czechia +6 Odyssey Therapeutics NCT06850727

Recruiting

Digitally Delivered Treatments to Reduce Chronic Low Back Pain

Low Back Pain Chronic Pain (Back / Neck) General Practice (GP), Primary Care Settings Digital Health +2

This study aims to evaluate the effectiveness of pain education and clinical hypnosis delivered via a mobile app compared to a guideline-informed factsheet for reducing pain and disability in people experiencing chronic low back pain attending general practice.

Начало: 02.06.2025 Край: 26.05.2028 Възраст: от 18 г. Treatment

Australia Neuroscience Research Australia NCT06984354

Recruiting

Kangaroo Care: Breastfeeding Success and Maternal Role

Breastfeeding Maternal Role Postpartum Care Kangaroo Care

Purpose: This is a randomized controlled trial designed to investigate the effects of Kangaroo Mother Care (KMC) applied in the early postpartum period to primiparous mothers on breastfeeding success and the perception of the maternal role. Methodology and Sample: Setting and Period: The study will be conducted at the Bucak State Hospital Delivery Unit between June 2025 and June 2026. Sample Size: Based on G\*Power analysis (alpha=0.05, power=80%, effect size d=0.566), a total of 112 mothers (56 intervention, 56 control) will be included, accounting for a 10% potential attrition rate. Participants will be assigned to groups using the sealed envelope method and randomization via www.random.org. Intervention: Experimental Group: Following routine care, the newborn will be placed in a "chest-to-chest" position on the mother's bare chest for Kangaroo Care. Intermittent KMC will be maintained for 24 hours, during which breastfeeding attempts will be supported. Control Group: Mothers and newborns will receive only the hospital's routine care (standard skin-to-skin contact and breastfeeding support). Data Collection Tools: Personal Information Form, Semantic Differential Scale-Myself as a Mother (to measure maternal role perception), LATCH Breastfeeding Assessment Tool (to evaluate breastfeeding success).

Начало: 01.06.2025 Край: 30.12.2026 Възраст: 18–49 г.

Turkey (Türkiye) Recep Tayyip Erdogan University NCT07543029

Recruiting Phase 4

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

ST-Segment Elevation Myocardial Infarction (STEMI) No-Reflow Phenomenon Coronary Slow Flow Acute Myocardial Infarction

Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.

Начало: 01.06.2025 Край: 31.12.2026 Възраст: 18–80 г.

Pakistan National Institute of Cardiovascular Diseases, Pakistan NCT07536802

Recruiting

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) MLL Rearrangement

The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is: • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.

Начало: 01.06.2025 Край: 07.04.2026 Възраст: 6–60 г.

China Peking University People's Hospital NCT07537738

Recruiting

Comparison of Two Surgical Methods (Winograd vs. Sleeve Method) in the Treatment of Ingrown Toenail.

Ingrown Toenail (Onychocryptosis)

This randomized clinical trial aims to compare the recurrence rates of two surgical techniques-Winograd procedure and sleeve (gutter) method-in the treatment of ingrown toenails (onychocryptosis). A total of 312 nails will be randomized into two groups, with patients receiving either the Winograd procedure or sleeve method. Participants will be followed for 30 days post-intervention to assess recurrence and other clinical outcomes. The study seeks to determine the more effective treatment modality for reducing recurrence in a tertiary care setting.

Начало: 01.06.2025 Край: 31.07.2026 Възраст: 12–75 г.

Pakistan Pakistan Institute of Medical Sciences NCT07547241

Recruiting Phase 1/2

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

Friedreich Ataxia

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

Начало: 01.06.2025 Край: 01.03.2027 Възраст: 18–65 г. Treatment

Australia Design Therapeutics, Inc. NCT06874010

Recruiting Phase 1

Lentiviral FIX Gene Therapy

Hemophilia B

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor IX into patients with hemophilia B, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Начало: 01.06.2025 Край: 01.06.2028 Възраст: 2–65 г.

China Shenzhen Geno-Immune Medical Institute NCT03961243

Recruiting Phase 1

Lentiviral FVIII Gene Therapy

Hemophilia A

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor VIII into patients with hemophilia A, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Начало: 01.06.2025 Край: 01.06.2028 Възраст: 2–65 г.

China Shenzhen Geno-Immune Medical Institute NCT03217032

1 … 90 91 92 93 94 … 222